Approaches to demonstration of Ebola virus vaccine efficacy

Affiliations

¹ Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: philip.krause@fda.hhs.gov.
² Anti-infectives and Vaccines, European Medicines Agency, London, UK.
³ Clinical Evaluation Division-Vaccines, Health Canada, Ottawa, ON, Canada.
⁴ Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Philip R Krause et al. Lancet Infect Dis. 2015 Jun.

. 2015 Jun;15(6):627-9.

doi: 10.1016/S1473-3099(15)00027-4. Epub 2015 May 17.

¹ Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: philip.krause@fda.hhs.gov.
² Anti-infectives and Vaccines, European Medicines Agency, London, UK.
³ Clinical Evaluation Division-Vaccines, Health Canada, Ottawa, ON, Canada.
⁴ Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.

No abstract available

MeSH terms